Will be separating it's consumer division from it's pharmaceutical and medical device division. What's everyone's take on this new direction? Johnson and Johnson is the world's largest health products companies by sales but believes that the two divisions directions and growth are diverging rapidly. Is this the right direction for them to take? No decision yet one what they will do when it comes to holding a stock offering.
I've always felt J n J was a safe long term hold how does this change that now? More growth potential with the pharmaceutical division but comes with more risk too. As the WSJ article states the consumer division comes with its own issues, as it's "Sales are growing more slowly than at the other businesses, and have lower margins too. "
Submitted November 12, 2021 at 06:52AM by Campfireandhotcocoa https://ift.tt/3okyGxO
